YY1: A novel therapeutic target for diabetic nephropathy orchestrated renal fibrosis

被引:37
|
作者
Yang, Tingting [1 ]
Shu, Fanglin [1 ]
Yang, Hao [1 ]
Heng, Cai [1 ]
Zhou, Yi [1 ]
Chen, Yibing [1 ]
Qian, Xuan [1 ]
Du, Lei [1 ]
Zhu, Xia [1 ]
Lu, Qian [1 ]
Yin, Xiaoxing [1 ]
机构
[1] Xuzhou Med Univ, Jiangsu Key Lab New Drug Res & Clin Pharm, Xuzhou 221004, Jiangsu, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
YY1; alpha-SMA; Diabetic nephropathy; Epithelial-mesenchymal transition; Renal fibrosis; EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR YY1; GROWTH-FACTOR-BETA; GENE-EXPRESSION; CANCER; PROGRESSION; ACTIVATION; RECEPTOR; ACCUMULATION; REPRESSION;
D O I
10.1016/j.metabol.2019.04.013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Renal fibrosis promotes the development of diabetic nephropathy (DN). A growing number of studies have reported that Yin Yang 1 (YY1), which is involved in cellular proliferation and differentiation, plays a crucial role in the pathogenesis of many diseases, such as pulmonary fibrosis, hepatic steatosis and cancer. Methods: We detected the expression of YY1 under various glucose concentration and time gradient conditions. Rapamycin was used to verify the mTORC1/p70S6K/YY1 signaling pathway in HK-2 cells. We used db/db mice to examine the connection between renal fibrosis and YY1. A luciferase assay and chromatin immunoprecipitation (ChIP) assay were used to identify whether YY1 directly regulated alpha-SMA by binding to the alpha-SMA promoter. RNA silencing and overexpression were performed by using a YY1 expression/knockdown plasmid to investigate the function of YY1 in renal fibrosis of DN. Results: YY1 expression and subsequent nuclear translocalion were upregulated in a glucose- and time-dependent manner via the mTORC1/p70SEK signaling pathway in HK-2 cells. YY1 expression and nuclear translocation was significantly upregulated in db/db mice. Furthermore, YY1 upregulated alpha-SMA expression and activity in high-glucose-cultured HK-2 cells. Overexpression of YY1 promoted renal fibrosis in db/m mice mainly by upregulating alpha-SMA expression and inducing epithelial-mesenchymal transition (EMT) in vitro and in vivo. Finally, downregulation of YY1 reversed renal fibrosis by improving EMT in vivo and in vitro. Conclusions: These results reveal that upregulation of YY1 plays a critical role in HG-induced deregulation of EMT-associated protein expression, which finally results in renal fibrosis of DN. Therefore, decreasing YY1 expression might represent a new therapeutic target for diabetic nephropathy-induced renal fibrosis. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:33 / 45
页数:13
相关论文
共 50 条
  • [31] The podocyte: a potential therapeutic target in diabetic nephropathy?
    Marshall, Sally M.
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (26) : 2713 - 2720
  • [32] Caveolin-1 in the Pathogenesis of Diabetic Nephropathy: Potential Therapeutic Target?
    Richard Van Krieken
    Joan C. Krepinsky
    Current Diabetes Reports, 2017, 17
  • [33] Caveolin-1 in the Pathogenesis of Diabetic Nephropathy: Potential Therapeutic Target?
    Van Krieken, Richard
    Krepinsky, Joan C.
    CURRENT DIABETES REPORTS, 2017, 17 (03)
  • [34] BMP4/Smad1 Signaling: A Novel Therapeutic Target for the Progression of Diabetic Nephropathy
    Matsubara, Takeshi
    Abe, Hideharu
    Tominaga, Tatsuya
    Jishage, Kou-ichi
    Mima, Akira
    Ueda, Otoya
    Araki, Makoto
    Torikoshi, Kazuo
    Nagai, Kojiro
    Goto, Chisato
    Kinosaki, Masahiko
    Iehara, Noriyuki
    Fukushima, Naoshi
    Fukastu, Atsushi
    Arai, Hidenori
    Doi, Toshio
    DIABETES, 2011, 60 : A2 - A2
  • [35] Prognostic significance of YY1 protein expression and mRNA levels by bioinformatics analysis in human cancers: A therapeutic target
    Bonavida, Benjamin
    Kaufhold, Samantha
    PHARMACOLOGY & THERAPEUTICS, 2015, 150 : 149 - 168
  • [36] YY1 downregulation underlies therapeutic response to molecular targeted agents
    Zhou, Shichao
    Zang, Jingyu
    Cai, Mei-Chun
    Ye, Kaiyan
    Liu, Jin
    Ma, Pengfei
    Wu, Jie
    Dai, Chenyang
    Lu, Haijiao
    Zhang, Qing
    Jiang, Junhong
    Chu, Tianqing
    Shen, Ying
    Tan, Li
    Zhuang, Guanglei
    Zhao, Xiaojing
    Wang, Lan
    Zhuang, Yu
    Fu, Yujie
    CELL DEATH & DISEASE, 2024, 15 (11):
  • [37] Thioredoxin-Interacting Protein: A Potential Therapeutic Target for Treatment of Progressive Fibrosis in Diabetic Nephropathy
    Tan, Christina Y. R.
    Weier, Qi
    Zhang, Yuan
    Cox, Alison J.
    Kelly, Darren J.
    Langham, Robyn G.
    NEPHRON, 2015, 129 (02) : 109 - 127
  • [38] Identification of histone deacetylase 8 as a novel therapeutic target for renal fibrosis
    Zhang, Yunhe
    Zou, Jianan
    Tolbert, Evelyn
    Zhao, Ting C.
    Bayliss, George
    Zhuang, Shougang
    FASEB JOURNAL, 2020, 34 (06): : 7295 - 7310
  • [39] Downregulation of miR-30c promotes renal fibrosis by target CTGF in diabetic nephropathy
    Wang, Jinyang
    Duan, Lijun
    Guo, Tiankang
    Gao, Yanbin
    Tian, Limin
    Liu, Jing
    Wang, Shaocheng
    Yang, Jinkui
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2016, 30 (03) : 406 - 414
  • [40] Neuropeptide YY1 receptor polymorphism as a prognostic predictor in Japanese patients with IgA nephropathy
    Ito, H
    Morita, T
    Suehiro, T
    Tahara, K
    Ikeda, Y
    Nakauchi, Y
    Makino, S
    Nishiya, K
    Hashimoto, K
    CLINICAL NEPHROLOGY, 1999, 51 (05) : 272 - 279